Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Resources
  • Blog

Revvityブログ

発見から治療までのイノベーションを促進

Latest

Introduction to 16S amplicon profiling.

NGS September 22, 2025 - 5 min read
Read
Disease Research

Epigenetic therapy shows promise as a companion for immunotherapy.

May 14, 2024 - 2 min read
Read
Disease Research, Neuroscience Research

A new human neuronal cell model of huntington’s disease for in vitro screening.

May 13, 2024 - 1 min read
Read
Disease Research

Definitive evidence of narcolepsy as an autoimmune disease.

May 13, 2024 - 1 min read
Read
Disease Research, Infectious Diseases

Now we have a COVID-19 vaccine, are treatments really needed.

May 10, 2024 - 2 min read
Read
Disease Research, Neuroscience Research

Engineered viral RNA gives boost to neurological disease research.

May 10, 2024 - 2 min read
Read
Disease Research

Dr. Helena Fehling: beating leishmania protozoan parasites with their own weapons.

May 10, 2024 - 2 min read
Read
Disease Research

Could nanomedicines be the answer to treating brain cancer?

May 10, 2024 - 3 min read
Read
Disease Research

Can we overcome the emergence of HIV drug resistance with novel inhibitors?

May 10, 2024 - 3 min read
Read
Disease Research

Novel approaches for overcoming antimicrobial resistance.

May 10, 2024 - 2 min read
Read
Disease Research

Next-generation antimalarial drugs urgently needed to reach malaria elimination targets.

May 10, 2024 - 3 min read
Read
Pagination
  • First page « 最初
  • Previous page Previous
  • ページ 1
  • ページ 2
  • ページ 3
  • Current page 4
  • ページ 5
  • ページ 6
  • Next page Next
  • Last page 最後 »

ご質問がございましたら、
お気軽にお問い合わせください。

お問合せ
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.